Kenneth S. Cohen to Neoplasms
This is a "connection" page, showing publications Kenneth S. Cohen has written about Neoplasms.
Connection Strength
0.641
-
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol. 2023 08 03; 25(8):1530-1545.
Score: 0.321
-
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Clin Cancer Res. 2019 12 15; 25(24):7294-7302.
Score: 0.061
-
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 09; 65(9):e27217.
Score: 0.056
-
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro Oncol. 2017 Oct 19; 19(11):1542-1552.
Score: 0.054
-
Response to Passos et al. Pediatr Neurol. 2014 Feb; 50(2):e3-4.
Score: 0.041
-
Hemorrhagic and ischemic stroke in children with cancer. Pediatr Neurol. 2013 Oct; 49(4):237-42.
Score: 0.040
-
Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 2010 Feb 15; 70(4):1534-43.
Score: 0.032
-
Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood. 2006 Apr 01; 107(7):2774-6.
Score: 0.024
-
Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency. J Pediatr Hematol Oncol. 2016 07; 38(5):360-6.
Score: 0.012